Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 128,302,056
  • Shares Outstanding, K 2,623,764
  • Annual Sales, $ 22,090 M
  • Annual Income, $ 2,155 M
  • 60-Month Beta 0.46
  • Price/Sales 5.32
  • Price/Cash Flow 15.34
  • Price/Book 9.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.51
  • Number of Estimates 3
  • High Estimate 0.52
  • Low Estimate 0.49
  • Prior Year 0.79
  • Growth Rate Est. (year over year) -35.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.61 +0.60%
on 01/27/20
51.55 -5.14%
on 01/17/20
-1.54 (-3.05%)
since 12/27/19
3-Month
46.31 +5.59%
on 11/08/19
51.55 -5.14%
on 01/17/20
+1.23 (+2.58%)
since 10/25/19
52-Week
35.30 +38.53%
on 01/28/19
51.55 -5.14%
on 01/17/20
+13.15 (+36.78%)
since 01/25/19

Most Recent Stories

More News
BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke

High-level results from the Phase III THALES trial showed AstraZeneca's BRILINTA (ticagrelor) 90 mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically...

AZN : 48.90 (-0.77%)
THLEY : 101.0000 (-8.18%)
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan (NYSE: AGN), a leading global pharmaceutical company, today announced that Allergan has entered into definitive agreements...

ABBV : 84.02 (+0.57%)
AZN : 48.90 (-0.77%)
AGN : 189.00 (+0.43%)
Roche's Urothelial Cancer Study on Tecentriq Disappoints

Roche's (RHHBY) study on Tecentriq in muscle-invasive urothelial cancer fails to meet goals.

MRK : 86.10 (+0.14%)
BMY : 63.70 (-0.72%)
AZN : 48.90 (-0.77%)
RHHBY : 40.9700 (-0.56%)
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU

J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.

MRK : 86.10 (+0.14%)
PFE : 40.16 (+0.85%)
AZN : 48.90 (-0.77%)
RHHBY : 40.9700 (-0.56%)
GSK : 46.48 (-1.59%)
JNJ : 148.75 (+0.29%)
NVS : 93.70 (-0.18%)
Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and the...

MRNA : 22.74 (+7.67%)
AZN : 48.90 (-0.77%)
MRK : 86.10 (+0.14%)
Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards?

While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.

MRK : 86.10 (+0.14%)
PFE : 40.16 (+0.85%)
AZN : 48.90 (-0.77%)
MYL : 21.16 (-3.16%)
5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

MRK : 86.10 (+0.14%)
ABBV : 84.02 (+0.57%)
AZN : 48.90 (-0.77%)
AMGN : 222.95 (-1.17%)
ALXN : 105.30 (+0.03%)
Gastro Esophageal Reflux Disease Drug and Devices Market 2019 Global Overview, Latest Technologies, Business Strategy, Key Vendors, Segments, Demands, Growth Factors, Size, Share by Forecast to 2025

A recent report provides crucial insights along with application based and forecast information in the Global Gastro Esophageal Reflux Disease Drug and Devices Market. The report provides a comprehensive...

AZN : 48.90 (-0.77%)
BSX : 42.65 (-1.30%)
CEMP : 2.33 (+1.30%)
STIM : 3.97 (-5.25%)
GSK : 46.48 (-1.59%)
IRWD : 12.18 (-1.54%)
MDGS : 1.89 (+1.34%)
MDT : 119.23 (-0.03%)
MRK : 86.10 (+0.14%)
NVS : 93.70 (-0.18%)
PFE : 40.16 (+0.85%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Top Stock Research Reports for Roche, Royal Dutch Shell & Citigroup

Top Stock Research Reports for Roche, Royal Dutch Shell & Citigroup

UNH : 284.09 (-2.98%)
RHHBY : 40.9700 (-0.56%)
RDS.A : 56.09 (-1.89%)
COST : 309.45 (-0.34%)
C : 76.71 (-2.18%)
AZN : 48.90 (-0.77%)
Myriad Submits sPMA for BRACAnalysis(R) CDx as a Companion Diagnostic for Lynparza(R) in Metastatic Castration-resistant Prostate Cancer

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food...

AZN : 48.90 (-0.77%)
MYGN : 28.43 (-0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 49.32
1st Resistance Point 49.11
Last Price 48.90
1st Support Level 48.65
2nd Support Level 48.40

See More

52-Week High 51.55
Last Price 48.90
Fibonacci 61.8% 45.34
Fibonacci 50% 43.42
Fibonacci 38.2% 41.51
52-Week Low 35.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar